文献速递病毒性肝炎

SLC22A1通过激活JAK/STAT通路抑制乙肝病毒并预测聚乙二醇干扰素α治疗慢性乙肝的疗效

SLC22A1 Resists Hepatitis B Virus by Activating the JAK/STAT Pathway and Predicts the Effect of Pegylated Interferon α-Based Therapy on Chronic Hepatitis B.
PubMed 文献 · J Infect Dis · 2025-01-01

研究探讨SLC22A1与慢性乙型肝炎的关系。对200例完成聚乙二醇干扰素α为基础治疗的患者(120例未治愈、80例治愈)在基线、12周和24周采集血浆,检测SLC22A1。结果显示HBV下调SLC22A1,SLC22A1通过激活JAK/STAT通路抑制HBV,24周血浆SLC22A1可预测功能性治愈(AUC 0.887),联合HBsAg预测更佳(AUC 0.925)。

要点

  • HBV下调SLC22A1表达,SLC22A1通过激活JAK/STAT通路抑制HBsAg和HBeAg。
  • 治愈组血浆SLC22A1动态升高,未治愈组无此变化。
  • 24周血浆SLC22A1预测功能性治愈AUC 0.887,联合24周HBsAg的AUC为0.925。

核心结论

  • HBV抑制SLC22A1表达,SLC22A1通过激活JAK/STAT通路抑制HBV。
  • SLC22A1是聚乙二醇干扰素α为基础治疗慢性乙型肝炎功能性治愈的预测指标。

研究设计与样本

  • 研究纳入200例完成聚乙二醇干扰素α为基础治疗的慢性乙型肝炎患者,其中未治愈120例、治愈80例。
  • 在基线、治疗12周和24周采集血浆,用ELISA检测血浆SLC22A1,用免疫组化检测健康对照和患者肝活检SLC22A1。
  • 进行RNA测序探索HBV和SLC22A1引起的变化,并在hepG2.2.15细胞中过表达SLC22A1进行体外实验。

主要发现

  • 比较有和无HBV的hepG2细胞以及慢性乙肝患者与健康志愿者的肝脏和血浆,显示SLC22A1被HBV下调。
  • 治愈组血浆SLC22A1动态升高,未治愈组无此变化。
  • 24周血浆SLC22A1预测功能性治愈的AUC为0.887,联合24周HBsAg的AUC为0.925。
  • 在hepG2.2.15细胞中过表达SLC22A1,通过激活JAK/STAT通路抑制HBsAg和HBeAg,与转录组测序结果一致。

关键数值与推荐

  • 24周血浆SLC22A1预测功能性治愈的AUC为0.887。
  • 24周血浆SLC22A1联合24周HBsAg预测功能性治愈的AUC为0.925。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Functional cure is the ideal treatment endpoint of chronic hepatitis B (CHB). Currently, only a few patients achieve this with treatment. Host differences must be influential. Solute carrier family 22 member 1 (SLC22A1), encoding organic cation transporter 1, is expressed in the liver and mediates substance transport of hepatocytes. The association between SLC22A1 and CHB has not been determined. Our objective was to elucidate this association. METHODS: RNA sequencing was performed to explore the changes caused by hepatitis B virus (HBV) and SLC22A1. Plasma from 200 patients with CHB (120 uncured, 80 cured) completing the pegylated interferon alpha (pegIFNα)-based treatment was collected at baseline and at 12 and 24 weeks of treatment. SLC22A1 of plasma and liver biopsies in healthy controls and patients with CHB were measured by enzyme-linked immunosorbent assay (ELISA) and immunohistochemistry. RESULTS: SLC22A1 was down-regulated by HBV, as indicated by comparing SLC22A1 of hepG2 cells with and without HBV and of both liver and plasma in CHB and healthy volunteers. Plasma SLC22A1 rose dynamically in the cured group but not in the uncured group. Plasma SLC22A1 at 24 weeks was predictive of functional cure (area under the receiver operating characteristic curve [AUC], 0.887) and better when combined with hepatitis B surface antigen (HBsAg) at 24 weeks (AUC, 0.925). In vitro experiments regarding overexpression of SLC22A1 in hepG2.2.15 demonstrated that HBsAg and hepatitis B e antigen were inhibited by SLC22A1 through JAK/STAT pathway activation, consistent with transcriptome sequencing results. CONCLUSIONS: HBV inhibits SLC22A1 expression and SLC22A1 suppresses HBV by activating the JAK/STAT pathway. SLC22A1 is a predictor of the functional cure of CHB with pegIFNα-based treatment.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Yu H, Li B, Guo H, et al. SLC22A1 Resists Hepatitis B Virus by Activating the JAK/STAT Pathway and Predicts the Effect of Pegylated Interferon α-Based Therapy on Chronic Hepatitis B. J Infect Dis. 2025. PMID: 40036258. doi:10.1093/infdis/jiaf102

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。